<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00111150</url>
  </required_header>
  <id_info>
    <org_study_id>CDC-NCHSTP-4321</org_study_id>
    <secondary_id>BOTUSA MB04</secondary_id>
    <nct_id>NCT00111150</nct_id>
  </id_info>
  <brief_title>Botswana Tenofovir Oral HIV Prophylaxis Trial</brief_title>
  <official_title>Study of the Safety and Efficacy of Daily Tenofovir Disoproxil Fumarate for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Botswana Ministry of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test whether taking a pill of tenofovir (an antiretroviral medicine) is safe&#xD;
      for sexually-active young adults in Botswana without HIV infection and whether it will reduce&#xD;
      their risk of getting an HIV infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twelve hundred healthy, sexually active women and men, 18-29 years old, without HIV infection&#xD;
      will be enrolled in Francistown and Gaborone, Botswana. They will be provided with free male&#xD;
      and female condoms, repeated individualized risk-reduction counseling, diagnosis and&#xD;
      treatment of sexually transmitted diseases, and women will be provided with a choice of&#xD;
      effective family planning methods. In addition, volunteers will be randomized to receive&#xD;
      either Tenofovir or a placebo pill to take once a day. Volunteers will be seen monthly for at&#xD;
      least 12 months to monitor for side effects and toxicities and to test their HIV status.&#xD;
      Persons who become HIV infected during the trial will receive ongoing supportive counseling,&#xD;
      CD4 and viral load monitoring, education about HIV infection/disease, and access to HIV care&#xD;
      including free antiretrovirals when clinically indicated. Volunteer safety will be monitored&#xD;
      by a local ethics committee, Centers for Disease Control Institutional Review Board (CDC IRB)&#xD;
      and an independent data safety and monitoring board.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Consenting participants entered tenofovir/emtricitabine oral prophylaxis trial&#xD;
  </why_stopped>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse drug reactions in the tenofovir and placebo arms</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV incidence in the tenofovir and placebo arms</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in levels of unprotected sex during the trial</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to medication</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiretroviral (ARV) resistance patterns in seroconverters</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral set point in seroconverters</measure>
  </secondary_outcome>
  <enrollment>1200</enrollment>
  <condition>HIV Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Disoproxil Fumarate 300 mg daily</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  citizen of Botswana 18-29 years old&#xD;
&#xD;
          -  sexually active&#xD;
&#xD;
          -  HIV uninfected&#xD;
&#xD;
          -  Hepatitis B and C uninfected&#xD;
&#xD;
          -  Calculated creatinine clearance &gt;= 60 mL/min&#xD;
&#xD;
          -  hemoglobin &gt;= 8 gm/dL&#xD;
&#xD;
          -  ALT and AST &lt;= 2x ULN&#xD;
&#xD;
          -  total bilirubin &lt;= 1.5 mg/dL&#xD;
&#xD;
          -  total serum amylase &lt;= 1.5x ULN&#xD;
&#xD;
          -  Serum phosphorus &gt;= 2.2 mg/dL&#xD;
&#xD;
          -  willing to use effective contraception&#xD;
&#xD;
          -  living within 1 hours travel of study clinic&#xD;
&#xD;
          -  pass comprehension test&#xD;
&#xD;
          -  willing and able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of significant renal or bone disease&#xD;
&#xD;
          -  any chronic illness requiring ongoing prescription medication&#xD;
&#xD;
          -  pregnant or breastfeeding&#xD;
&#xD;
          -  planning to move away from site in the next year&#xD;
&#xD;
          -  participating in another HIV prevention or vaccine safety trial&#xD;
&#xD;
          -  any other clinical condition or prior therapy that, in the opinion of the study&#xD;
             physician, would make the volunteer unsuitable for the study or unable to comply with&#xD;
             the dosing requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dawn K Smith, MD, MS, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>CDC and BOTUSA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lynn A Paxton, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centers for Disease Control and Prevention</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30333</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BOTUSA HIV Prevention Research Unit</name>
      <address>
        <city>Francistown and Gaborone</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Botswana</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <study_first_submitted>May 17, 2005</study_first_submitted>
  <study_first_submitted_qc>May 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2005</study_first_posted>
  <last_update_submitted>March 16, 2007</last_update_submitted>
  <last_update_submitted_qc>March 16, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2007</last_update_posted>
  <keyword>HIV incidence</keyword>
  <keyword>HIV prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

